Price comparison of high-cost originator medicines in European countries.
Identifieur interne : 001B16 ( Ncbi/Merge ); précédent : 001B15; suivant : 001B17Price comparison of high-cost originator medicines in European countries.
Auteurs : Sabine Vogler [Autriche] ; Nina Zimmermann [Autriche] ; Zaheer-Ud-Din Babar [Nouvelle-Zélande]Source :
- Expert review of pharmacoeconomics & outcomes research [ 1744-8379 ] ; 2016.
Abstract
In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-income countries.
DOI: 10.1080/14737167.2016.1223543
PubMed: 27658050
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000075
- to stream PubMed, to step Curation: 000075
- to stream PubMed, to step Checkpoint: 000075
Links to Exploration step
pubmed:27658050Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Price comparison of high-cost originator medicines in European countries.</title><author><name sortKey="Vogler, Sabine" sort="Vogler, Sabine" uniqKey="Vogler S" first="Sabine" last="Vogler">Sabine Vogler</name><affiliation wicri:level="1"><nlm:affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Zimmermann, Nina" sort="Zimmermann, Nina" uniqKey="Zimmermann N" first="Nina" last="Zimmermann">Nina Zimmermann</name><affiliation wicri:level="1"><nlm:affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Babar, Zaheer Ud Din" sort="Babar, Zaheer Ud Din" uniqKey="Babar Z" first="Zaheer-Ud-Din" last="Babar">Zaheer-Ud-Din Babar</name><affiliation wicri:level="1"><nlm:affiliation>b Division of Pharmacy Practice, School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Auckland , New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>b Division of Pharmacy Practice, School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Auckland </wicri:regionArea><wicri:noRegion>Auckland </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27658050</idno><idno type="pmid">27658050</idno><idno type="doi">10.1080/14737167.2016.1223543</idno><idno type="wicri:Area/PubMed/Corpus">000075</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000075</idno><idno type="wicri:Area/PubMed/Curation">000075</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000075</idno><idno type="wicri:Area/PubMed/Checkpoint">000075</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000075</idno><idno type="wicri:Area/Ncbi/Merge">001B16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Price comparison of high-cost originator medicines in European countries.</title><author><name sortKey="Vogler, Sabine" sort="Vogler, Sabine" uniqKey="Vogler S" first="Sabine" last="Vogler">Sabine Vogler</name><affiliation wicri:level="1"><nlm:affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Zimmermann, Nina" sort="Zimmermann, Nina" uniqKey="Zimmermann N" first="Nina" last="Zimmermann">Nina Zimmermann</name><affiliation wicri:level="1"><nlm:affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna </wicri:regionArea><wicri:noRegion>Vienna </wicri:noRegion></affiliation></author><author><name sortKey="Babar, Zaheer Ud Din" sort="Babar, Zaheer Ud Din" uniqKey="Babar Z" first="Zaheer-Ud-Din" last="Babar">Zaheer-Ud-Din Babar</name><affiliation wicri:level="1"><nlm:affiliation>b Division of Pharmacy Practice, School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Auckland , New Zealand.</nlm:affiliation><country xml:lang="fr">Nouvelle-Zélande</country><wicri:regionArea>b Division of Pharmacy Practice, School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Auckland </wicri:regionArea><wicri:noRegion>Auckland </wicri:noRegion></affiliation></author></analytic><series><title level="j">Expert review of pharmacoeconomics & outcomes research</title><idno type="eISSN">1744-8379</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-income countries.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">27658050</PMID><DateCreated><Year>2016</Year><Month>09</Month><Day>23</Day></DateCreated><DateRevised><Year>2016</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-8379</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2016</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Expert review of pharmacoeconomics & outcomes research</Title><ISOAbbreviation>Expert Rev Pharmacoecon Outcomes Res</ISOAbbreviation></Journal><ArticleTitle>Price comparison of high-cost originator medicines in European countries.</ArticleTitle><Pagination><MedlinePgn>1-10</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In recent years, high-cost medicines have increasingly been challenging the public health budget in all countries including high-income economies. In this context, this study aims to survey, analyze and compare prices of medicines that likely contribute to high expenditure for the public payers in high-income countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We chose the following 16 European countries: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Portugal, Sweden, Slovakia, Spain and United Kingdom. The ex-factory price data of 30 medicines in these countries were collected in national databases accessible through the Pharmaceutical Price Information (PPI) service of Gesundheit Österreich GmbH (Austrian Public Health Institute).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The ex-factory prices (median) per unit (e.g. per tablet, vial) ranged from 10.67 cent (levodopa + decarboxylase inhibitor) to 17,000 euro (ipilimumab). A total of 53% of the medicines surveyed had a unit ex-factory price (median) above 200 Euro. For two thirds of the medicines, price differences between the highest-priced country and lowest-priced country ranged between 25 and 100%; the remaining medicines, mainly low-priced medicines, had higher price differential, up to 251%. Medicines with unit prices of a few euros or less were medicines for the treatment of diseases in the nervous system (anti-depressants, medicines to treat Parkinson and for the management of neuropathic pain), of obstructive airway diseases and cardio-vascular medicines (lipid modifying agents). High-priced medicines were particularly cancer medicines.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Medicine prices of Greece, Hungary, Slovakia and UK were frequently at the lower end, German and Swedish, as well as Danish and Irish prices at the upper end. For high-priced medicines, actual paid prices are likely to be lower due to confidential discounts and similar funding arrangements between industry and public payers. Pricing authorities refer to the higher undiscounted prices when they use price data from other countries for their pricing decisions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vogler</LastName><ForeName>Sabine</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>a WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Health Economics Department , Gesundheit Österreich GmbH (Austrian Public Health Institute) , Vienna , Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babar</LastName><ForeName>Zaheer-Ud-Din</ForeName><Initials>ZU</Initials><AffiliationInfo><Affiliation>b Division of Pharmacy Practice, School of Pharmacy, Faculty of Medical and Health Sciences , University of Auckland , Auckland , New Zealand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Lahore Pharmacy College (A project of Lahore Medical and Dental College) , Tulspura Canal Bank , Lahore 53400 , Pakistan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Pharmacoecon Outcomes Res</MedlineTA><NlmUniqueID>101132257</NlmUniqueID><ISSNLinking>1473-7167</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Europe</Keyword><Keyword MajorTopicYN="N">High-cost medicines</Keyword><Keyword MajorTopicYN="N">comparison</Keyword><Keyword MajorTopicYN="N">discounts</Keyword><Keyword MajorTopicYN="N">external price referencing</Keyword><Keyword MajorTopicYN="N">medicine prices</Keyword><Keyword MajorTopicYN="N">price analysis</Keyword><Keyword MajorTopicYN="N">price study</Keyword><Keyword MajorTopicYN="N">price survey</Keyword><Keyword MajorTopicYN="N">transparency</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>9</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>9</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27658050</ArticleId><ArticleId IdType="doi">10.1080/14737167.2016.1223543</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li><li>Nouvelle-Zélande</li></country></list><tree><country name="Autriche"><noRegion><name sortKey="Vogler, Sabine" sort="Vogler, Sabine" uniqKey="Vogler S" first="Sabine" last="Vogler">Sabine Vogler</name></noRegion><name sortKey="Zimmermann, Nina" sort="Zimmermann, Nina" uniqKey="Zimmermann N" first="Nina" last="Zimmermann">Nina Zimmermann</name></country><country name="Nouvelle-Zélande"><noRegion><name sortKey="Babar, Zaheer Ud Din" sort="Babar, Zaheer Ud Din" uniqKey="Babar Z" first="Zaheer-Ud-Din" last="Babar">Zaheer-Ud-Din Babar</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B16 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001B16 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:27658050
|texte= Price comparison of high-cost originator medicines in European countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27658050" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |